CLINICAL TRIAL OVERVIEW
TAZVERIK® efficacy and safety were evaluated in two open-label, single-arm cohorts (Cohort 4 and 5) of a multicenter study in patients with histologically confirmed follicular lymphoma after at least 2 prior systemic therapies (n=99). The primary efficacy endpoint was the overall response rate (ORR) and a secondary efficacy endpoint was duration of response (DOR).1,2
TAZVERIK DEMONSTRATED EFFICACY, REGARDLESS OF EZH2 MUTATION STATUS
Wild-Type EZH2 Follicular Lymphoma
*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by Independent Review Committee.
†Percentages are based on the Intent-to-Treat subjects within each group that achieved a complete response or partial response.
EXPLORATORY SUBANALYSIS OF THE PRIMARY ENDPOINT:
CHANGE IN TUMOR VOLUME
Wild-Type EZH2 Follicular Lymphoma


‡ The tumor volume was measured based on the maximum reduction in the sum of the products of the perpendicular diameters. Figure shown only includes patients (with 2+ prior systemic therapies) with baseline and post-baseline tumor measurements by the IRC; 1 patient did not have change from baseline.
Mutant EZH2 Follicular Lymphoma


§The tumor volume was measured based on the maximum reduction in the sum of the products of the perpendicular diameters.
LIMITATIONS: These additional data from the phase 2, single-arm study represent a subanalysis of maximum percent tumor volume change by participant. Tumor volume reduction is not equivalent to overall response, which requires at least 50% volume reduction and no new lesions per IWG-NHL criteria. Conclusions regarding the primary endpoint of the study should not be drawn from this representation of the data.
EZH2=enhancer of zeste homolog 2; WT=wild-type; MT=mutant-type; ORR=overall response rate; CI=confidence interval; DOR=duration of response; NE=not estimable; IRC=independent review committee.
References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Data on file.